Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia
The telomerase complex is responsible for telomere maintenance and represents a promising neoplasia therapeutic target. Recently, we have demonstrated that treatment with a G-quadruplex-interactive agent, telomestatin reproducibly inhibited telomerase activity in the BCR-ABL-positive leukemic cell l...
Gespeichert in:
| Veröffentlicht in: | Oncogene 2006-09, Vol.25 (42), p.5719-5725 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5725 |
|---|---|
| container_issue | 42 |
| container_start_page | 5719 |
| container_title | Oncogene |
| container_volume | 25 |
| creator | Tauchi, T Shin-ya, K Sashida, G Sumi, M Okabe, S Ohyashiki, J H Ohyashiki, K |
| description | The telomerase complex is responsible for telomere maintenance and represents a promising neoplasia therapeutic target. Recently, we have demonstrated that treatment with a G-quadruplex-interactive agent, telomestatin reproducibly inhibited telomerase activity in the BCR-ABL-positive leukemic cell lines. In the present study, we investigated the mechanisms of apoptosis induced by telomerase inhibition in acute leukemia. We have found the activation of caspase-3 and poly-(ADP-ribose) polymerase in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25). Activation of p38 mitogen-activated protein (MAP) kinase and MKK3/6 was also found in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25); however, activation of JNK and ASK1 was not detected in these cells. To examine the effect of p38 MAP kinase inhibition on growth properties and apoptosis in telomerase-inhibited cells, we cultured DN-hTERT-expressing U937 cells with or without SB203580. Dominant-negative-hTERT-expressing U937 cells stopped proliferation on PD25; however, a significant increase in growth rate was observed in the presence of SB203580. Treatment of SB203580 also reduced the induction of apoptosis in DN-hTERT-expressing U937 cells (PD25). These results suggest that p38 MAP kinase has a critical role for the induction of apoptosis in telomerase-inhibited leukemia cells. Further, we evaluated the effect of telomestatin on the growth of U937 cells in xenograft mouse model. Systemic intraperitoneal administration of telomestatin in U937 xenografts decreased tumor telomerase levels and reduced tumor volumes. Tumor tissue from telomestatin-treated animals exhibited marked apoptosis. None of the mice treated with telomestatin displayed any signs of toxicity. Taken together, these results lay the foundations for a program of drug development to achieve the dual aims of efficacy and selectivity
in vivo
. |
| doi_str_mv | 10.1038/sj.onc.1209577 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_21306233</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A189054582</galeid><sourcerecordid>A189054582</sourcerecordid><originalsourceid>FETCH-LOGICAL-c547t-6d5f8fdb1c856f20f6aa003d6614a2043a931800c6c74ca8ef5b8196999825b83</originalsourceid><addsrcrecordid>eNqFklFvFCEQxzdGY8_qq4-GaPTJvQK7wOJb09hq0sSX-kw4Fq6cu3AF9tQnv7pzvU0uMW0MDzDDb_4zA1NVrwleEtx0Z3mzjMEsCcWSCfGkWpBW8Jox2T6tFuDDtaQNPale5LzBGAuJ6fPqhHDOKGHtovpzY4c42qSzRT7c-pUvPgb005dbpFGIOzugq_pu0n2atoP9VftQgDbF7yzSaxvKR1TuJXLRxYdPoIJ2vqSIdOgPxi6iXKbe27y3tZmKRYOdftjR65fVM6eHbF_N-2n1_fLzzcWX-vrb1deL8-vasFaUmvfMda5fEdMx7ih2XGuMm55z0mqK20bLhnQYG25Ea3RnHVt1RHIpZUfh2JxWHw662xTvJihWjT4bOww62DhlRUmDOW2a_4JEihZIAeC7f8BNnFKAJhTlLWkEkByot49SIMIxF_IotdaDVT64WOCJ93nVOekkZi3rKFDLByhYPTykicE6D_6HAkyKOSfr1Db5UaffimC1nx6VNwqmR83TAwFv5mKn1Wj7Iz6PCwDvZ0BnoweXdDA-H7mOUAkfBNzZgctwFdY2Hbt-JPVfp8fb2w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>227360679</pqid></control><display><type>article</type><title>Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Tauchi, T ; Shin-ya, K ; Sashida, G ; Sumi, M ; Okabe, S ; Ohyashiki, J H ; Ohyashiki, K</creator><creatorcontrib>Tauchi, T ; Shin-ya, K ; Sashida, G ; Sumi, M ; Okabe, S ; Ohyashiki, J H ; Ohyashiki, K</creatorcontrib><description>The telomerase complex is responsible for telomere maintenance and represents a promising neoplasia therapeutic target. Recently, we have demonstrated that treatment with a G-quadruplex-interactive agent, telomestatin reproducibly inhibited telomerase activity in the BCR-ABL-positive leukemic cell lines. In the present study, we investigated the mechanisms of apoptosis induced by telomerase inhibition in acute leukemia. We have found the activation of caspase-3 and poly-(ADP-ribose) polymerase in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25). Activation of p38 mitogen-activated protein (MAP) kinase and MKK3/6 was also found in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25); however, activation of JNK and ASK1 was not detected in these cells. To examine the effect of p38 MAP kinase inhibition on growth properties and apoptosis in telomerase-inhibited cells, we cultured DN-hTERT-expressing U937 cells with or without SB203580. Dominant-negative-hTERT-expressing U937 cells stopped proliferation on PD25; however, a significant increase in growth rate was observed in the presence of SB203580. Treatment of SB203580 also reduced the induction of apoptosis in DN-hTERT-expressing U937 cells (PD25). These results suggest that p38 MAP kinase has a critical role for the induction of apoptosis in telomerase-inhibited leukemia cells. Further, we evaluated the effect of telomestatin on the growth of U937 cells in xenograft mouse model. Systemic intraperitoneal administration of telomestatin in U937 xenografts decreased tumor telomerase levels and reduced tumor volumes. Tumor tissue from telomestatin-treated animals exhibited marked apoptosis. None of the mice treated with telomestatin displayed any signs of toxicity. Taken together, these results lay the foundations for a program of drug development to achieve the dual aims of efficacy and selectivity
in vivo
.</description><identifier>ISSN: 0950-9232</identifier><identifier>EISSN: 1476-5594</identifier><identifier>DOI: 10.1038/sj.onc.1209577</identifier><identifier>PMID: 16652154</identifier><identifier>CODEN: ONCNES</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Acute Disease ; Ageing, cell death ; Animals ; Antineoplastic Agents - pharmacology ; Apoptosis ; BCR-ABL protein ; Biological and medical sciences ; Caspase-3 ; Cell activation ; Cell Biology ; Cell physiology ; Cell proliferation ; Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes ; Drug development ; Enzymes ; Fundamental and applied biological sciences. Psychology ; Fusion protein ; Gene expression ; Growth rate ; GTP-Binding Proteins - drug effects ; GTP-Binding Proteins - metabolism ; Human Genetics ; Humans ; Inhibitor drugs ; Internal Medicine ; Kinases ; Kinetics ; Leukemia ; Leukemia - drug therapy ; MAP kinase ; Medicine ; Medicine & Public Health ; MKK3 protein ; Molecular and cellular biology ; Oncology ; original-article ; Oxazoles - pharmacology ; Pharmacology ; Ribose ; Telomerase ; Telomerase - antagonists & inhibitors ; Telomerase reverse transcriptase ; Telomeres ; Therapeutic targets ; Toxicity ; Transplantation, Heterologous ; Tumors ; U937 Cells ; Xenografts</subject><ispartof>Oncogene, 2006-09, Vol.25 (42), p.5719-5725</ispartof><rights>Springer Nature Limited 2006</rights><rights>2006 INIST-CNRS</rights><rights>COPYRIGHT 2006 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Sep 21, 2006</rights><rights>Nature Publishing Group 2006.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c547t-6d5f8fdb1c856f20f6aa003d6614a2043a931800c6c74ca8ef5b8196999825b83</citedby><cites>FETCH-LOGICAL-c547t-6d5f8fdb1c856f20f6aa003d6614a2043a931800c6c74ca8ef5b8196999825b83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/sj.onc.1209577$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/sj.onc.1209577$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18129856$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16652154$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tauchi, T</creatorcontrib><creatorcontrib>Shin-ya, K</creatorcontrib><creatorcontrib>Sashida, G</creatorcontrib><creatorcontrib>Sumi, M</creatorcontrib><creatorcontrib>Okabe, S</creatorcontrib><creatorcontrib>Ohyashiki, J H</creatorcontrib><creatorcontrib>Ohyashiki, K</creatorcontrib><title>Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia</title><title>Oncogene</title><addtitle>Oncogene</addtitle><addtitle>Oncogene</addtitle><description>The telomerase complex is responsible for telomere maintenance and represents a promising neoplasia therapeutic target. Recently, we have demonstrated that treatment with a G-quadruplex-interactive agent, telomestatin reproducibly inhibited telomerase activity in the BCR-ABL-positive leukemic cell lines. In the present study, we investigated the mechanisms of apoptosis induced by telomerase inhibition in acute leukemia. We have found the activation of caspase-3 and poly-(ADP-ribose) polymerase in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25). Activation of p38 mitogen-activated protein (MAP) kinase and MKK3/6 was also found in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25); however, activation of JNK and ASK1 was not detected in these cells. To examine the effect of p38 MAP kinase inhibition on growth properties and apoptosis in telomerase-inhibited cells, we cultured DN-hTERT-expressing U937 cells with or without SB203580. Dominant-negative-hTERT-expressing U937 cells stopped proliferation on PD25; however, a significant increase in growth rate was observed in the presence of SB203580. Treatment of SB203580 also reduced the induction of apoptosis in DN-hTERT-expressing U937 cells (PD25). These results suggest that p38 MAP kinase has a critical role for the induction of apoptosis in telomerase-inhibited leukemia cells. Further, we evaluated the effect of telomestatin on the growth of U937 cells in xenograft mouse model. Systemic intraperitoneal administration of telomestatin in U937 xenografts decreased tumor telomerase levels and reduced tumor volumes. Tumor tissue from telomestatin-treated animals exhibited marked apoptosis. None of the mice treated with telomestatin displayed any signs of toxicity. Taken together, these results lay the foundations for a program of drug development to achieve the dual aims of efficacy and selectivity
in vivo
.</description><subject>Acute Disease</subject><subject>Ageing, cell death</subject><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis</subject><subject>BCR-ABL protein</subject><subject>Biological and medical sciences</subject><subject>Caspase-3</subject><subject>Cell activation</subject><subject>Cell Biology</subject><subject>Cell physiology</subject><subject>Cell proliferation</subject><subject>Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes</subject><subject>Drug development</subject><subject>Enzymes</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fusion protein</subject><subject>Gene expression</subject><subject>Growth rate</subject><subject>GTP-Binding Proteins - drug effects</subject><subject>GTP-Binding Proteins - metabolism</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Inhibitor drugs</subject><subject>Internal Medicine</subject><subject>Kinases</subject><subject>Kinetics</subject><subject>Leukemia</subject><subject>Leukemia - drug therapy</subject><subject>MAP kinase</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>MKK3 protein</subject><subject>Molecular and cellular biology</subject><subject>Oncology</subject><subject>original-article</subject><subject>Oxazoles - pharmacology</subject><subject>Pharmacology</subject><subject>Ribose</subject><subject>Telomerase</subject><subject>Telomerase - antagonists & inhibitors</subject><subject>Telomerase reverse transcriptase</subject><subject>Telomeres</subject><subject>Therapeutic targets</subject><subject>Toxicity</subject><subject>Transplantation, Heterologous</subject><subject>Tumors</subject><subject>U937 Cells</subject><subject>Xenografts</subject><issn>0950-9232</issn><issn>1476-5594</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFklFvFCEQxzdGY8_qq4-GaPTJvQK7wOJb09hq0sSX-kw4Fq6cu3AF9tQnv7pzvU0uMW0MDzDDb_4zA1NVrwleEtx0Z3mzjMEsCcWSCfGkWpBW8Jox2T6tFuDDtaQNPale5LzBGAuJ6fPqhHDOKGHtovpzY4c42qSzRT7c-pUvPgb005dbpFGIOzugq_pu0n2atoP9VftQgDbF7yzSaxvKR1TuJXLRxYdPoIJ2vqSIdOgPxi6iXKbe27y3tZmKRYOdftjR65fVM6eHbF_N-2n1_fLzzcWX-vrb1deL8-vasFaUmvfMda5fEdMx7ih2XGuMm55z0mqK20bLhnQYG25Ea3RnHVt1RHIpZUfh2JxWHw662xTvJihWjT4bOww62DhlRUmDOW2a_4JEihZIAeC7f8BNnFKAJhTlLWkEkByot49SIMIxF_IotdaDVT64WOCJ93nVOekkZi3rKFDLByhYPTykicE6D_6HAkyKOSfr1Db5UaffimC1nx6VNwqmR83TAwFv5mKn1Wj7Iz6PCwDvZ0BnoweXdDA-H7mOUAkfBNzZgctwFdY2Hbt-JPVfp8fb2w</recordid><startdate>20060921</startdate><enddate>20060921</enddate><creator>Tauchi, T</creator><creator>Shin-ya, K</creator><creator>Sashida, G</creator><creator>Sumi, M</creator><creator>Okabe, S</creator><creator>Ohyashiki, J H</creator><creator>Ohyashiki, K</creator><general>Nature Publishing Group UK</general><general>Nature Publishing</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7T5</scope></search><sort><creationdate>20060921</creationdate><title>Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia</title><author>Tauchi, T ; Shin-ya, K ; Sashida, G ; Sumi, M ; Okabe, S ; Ohyashiki, J H ; Ohyashiki, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c547t-6d5f8fdb1c856f20f6aa003d6614a2043a931800c6c74ca8ef5b8196999825b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Acute Disease</topic><topic>Ageing, cell death</topic><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis</topic><topic>BCR-ABL protein</topic><topic>Biological and medical sciences</topic><topic>Caspase-3</topic><topic>Cell activation</topic><topic>Cell Biology</topic><topic>Cell physiology</topic><topic>Cell proliferation</topic><topic>Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes</topic><topic>Drug development</topic><topic>Enzymes</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fusion protein</topic><topic>Gene expression</topic><topic>Growth rate</topic><topic>GTP-Binding Proteins - drug effects</topic><topic>GTP-Binding Proteins - metabolism</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Inhibitor drugs</topic><topic>Internal Medicine</topic><topic>Kinases</topic><topic>Kinetics</topic><topic>Leukemia</topic><topic>Leukemia - drug therapy</topic><topic>MAP kinase</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>MKK3 protein</topic><topic>Molecular and cellular biology</topic><topic>Oncology</topic><topic>original-article</topic><topic>Oxazoles - pharmacology</topic><topic>Pharmacology</topic><topic>Ribose</topic><topic>Telomerase</topic><topic>Telomerase - antagonists & inhibitors</topic><topic>Telomerase reverse transcriptase</topic><topic>Telomeres</topic><topic>Therapeutic targets</topic><topic>Toxicity</topic><topic>Transplantation, Heterologous</topic><topic>Tumors</topic><topic>U937 Cells</topic><topic>Xenografts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tauchi, T</creatorcontrib><creatorcontrib>Shin-ya, K</creatorcontrib><creatorcontrib>Sashida, G</creatorcontrib><creatorcontrib>Sumi, M</creatorcontrib><creatorcontrib>Okabe, S</creatorcontrib><creatorcontrib>Ohyashiki, J H</creatorcontrib><creatorcontrib>Ohyashiki, K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>Immunology Abstracts</collection><jtitle>Oncogene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tauchi, T</au><au>Shin-ya, K</au><au>Sashida, G</au><au>Sumi, M</au><au>Okabe, S</au><au>Ohyashiki, J H</au><au>Ohyashiki, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia</atitle><jtitle>Oncogene</jtitle><stitle>Oncogene</stitle><addtitle>Oncogene</addtitle><date>2006-09-21</date><risdate>2006</risdate><volume>25</volume><issue>42</issue><spage>5719</spage><epage>5725</epage><pages>5719-5725</pages><issn>0950-9232</issn><eissn>1476-5594</eissn><coden>ONCNES</coden><abstract>The telomerase complex is responsible for telomere maintenance and represents a promising neoplasia therapeutic target. Recently, we have demonstrated that treatment with a G-quadruplex-interactive agent, telomestatin reproducibly inhibited telomerase activity in the BCR-ABL-positive leukemic cell lines. In the present study, we investigated the mechanisms of apoptosis induced by telomerase inhibition in acute leukemia. We have found the activation of caspase-3 and poly-(ADP-ribose) polymerase in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25). Activation of p38 mitogen-activated protein (MAP) kinase and MKK3/6 was also found in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25); however, activation of JNK and ASK1 was not detected in these cells. To examine the effect of p38 MAP kinase inhibition on growth properties and apoptosis in telomerase-inhibited cells, we cultured DN-hTERT-expressing U937 cells with or without SB203580. Dominant-negative-hTERT-expressing U937 cells stopped proliferation on PD25; however, a significant increase in growth rate was observed in the presence of SB203580. Treatment of SB203580 also reduced the induction of apoptosis in DN-hTERT-expressing U937 cells (PD25). These results suggest that p38 MAP kinase has a critical role for the induction of apoptosis in telomerase-inhibited leukemia cells. Further, we evaluated the effect of telomestatin on the growth of U937 cells in xenograft mouse model. Systemic intraperitoneal administration of telomestatin in U937 xenografts decreased tumor telomerase levels and reduced tumor volumes. Tumor tissue from telomestatin-treated animals exhibited marked apoptosis. None of the mice treated with telomestatin displayed any signs of toxicity. Taken together, these results lay the foundations for a program of drug development to achieve the dual aims of efficacy and selectivity
in vivo
.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>16652154</pmid><doi>10.1038/sj.onc.1209577</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-9232 |
| ispartof | Oncogene, 2006-09, Vol.25 (42), p.5719-5725 |
| issn | 0950-9232 1476-5594 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_21306233 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Acute Disease Ageing, cell death Animals Antineoplastic Agents - pharmacology Apoptosis BCR-ABL protein Biological and medical sciences Caspase-3 Cell activation Cell Biology Cell physiology Cell proliferation Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes Drug development Enzymes Fundamental and applied biological sciences. Psychology Fusion protein Gene expression Growth rate GTP-Binding Proteins - drug effects GTP-Binding Proteins - metabolism Human Genetics Humans Inhibitor drugs Internal Medicine Kinases Kinetics Leukemia Leukemia - drug therapy MAP kinase Medicine Medicine & Public Health MKK3 protein Molecular and cellular biology Oncology original-article Oxazoles - pharmacology Pharmacology Ribose Telomerase Telomerase - antagonists & inhibitors Telomerase reverse transcriptase Telomeres Therapeutic targets Toxicity Transplantation, Heterologous Tumors U937 Cells Xenografts |
| title | Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T19%3A48%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Telomerase%20inhibition%20with%20a%20novel%20G-quadruplex-interactive%20agent,%20telomestatin:%20in%20vitro%20and%20in%20vivo%20studies%20in%20acute%20leukemia&rft.jtitle=Oncogene&rft.au=Tauchi,%20T&rft.date=2006-09-21&rft.volume=25&rft.issue=42&rft.spage=5719&rft.epage=5725&rft.pages=5719-5725&rft.issn=0950-9232&rft.eissn=1476-5594&rft.coden=ONCNES&rft_id=info:doi/10.1038/sj.onc.1209577&rft_dat=%3Cgale_proqu%3EA189054582%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=227360679&rft_id=info:pmid/16652154&rft_galeid=A189054582&rfr_iscdi=true |